219 related articles for article (PubMed ID: 36252024)
21. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
23. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
24. Monobodies as tool biologics for accelerating target validation and druggable site discovery.
Akkapeddi P; Teng KW; Koide S
RSC Med Chem; 2021 Nov; 12(11):1839-1853. PubMed ID: 34820623
[TBL] [Abstract][Full Text] [Related]
25. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
26. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
[TBL] [Abstract][Full Text] [Related]
27. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Ostrem JM; Peters U; Sos ML; Wells JA; Shokat KM
Nature; 2013 Nov; 503(7477):548-51. PubMed ID: 24256730
[TBL] [Abstract][Full Text] [Related]
28. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
[TBL] [Abstract][Full Text] [Related]
29. Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D.
Kumar SU; Priya Doss CG
Comput Biol Med; 2021 Dec; 139():104946. PubMed ID: 34715554
[TBL] [Abstract][Full Text] [Related]
30. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.
Hunter JC; Gurbani D; Ficarro SB; Carrasco MA; Lim SM; Choi HG; Xie T; Marto JA; Chen Z; Gray NS; Westover KD
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8895-900. PubMed ID: 24889603
[TBL] [Abstract][Full Text] [Related]
31. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
[No Abstract] [Full Text] [Related]
32. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Chen H; Smaill JB; Liu T; Ding K; Lu X
J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
[TBL] [Abstract][Full Text] [Related]
33. Modeling receptor flexibility in the structure-based design of KRAS
Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
[TBL] [Abstract][Full Text] [Related]
34. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.
Wang A; Liu J; Li X; Zou F; Qi Z; Qi S; Liu Q; Wang Z; Cao J; Jiang Z; Wang B; Ge J; Wang L; Wang W; Liu J; Liu Q
Eur J Pharmacol; 2023 Aug; 952():175752. PubMed ID: 37164118
[TBL] [Abstract][Full Text] [Related]
36. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
Kirschner T; Müller MP; Rauh D
J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
[TBL] [Abstract][Full Text] [Related]
37. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.
Lu J; Harrison RA; Li L; Zeng M; Gondi S; Scott D; Gray NS; Engen JR; Westover KD
Structure; 2017 Sep; 25(9):1442-1448.e3. PubMed ID: 28781083
[TBL] [Abstract][Full Text] [Related]
38. Crystal Packing Reveals a Potential Autoinhibited KRAS Dimer Interface and a Strategy for Small-Molecule Inhibition of RAS Signaling.
Brenner RJ; Landgraf AD; Bum-Erdene K; Gonzalez-Gutierrez G; Meroueh SO
Biochemistry; 2023 Nov; 62(22):3206-3213. PubMed ID: 37938120
[TBL] [Abstract][Full Text] [Related]
39. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
[TBL] [Abstract][Full Text] [Related]
40. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach.
Kumar S U; Varghese RP; Preethi VA; Doss CGP; Zayed H
Front Biosci (Landmark Ed); 2023 Nov; 28(11):288. PubMed ID: 38062837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]